These medications may be coadministered without dose adjustment and without increased monitoring. Select Outpatient Medications Not Expected to Have Clinically Relevant Interactions With Ritonavir-Boosted Nirmatrelvir (Paxlovid) Medications Without Clinically Relevant Interactions This is not a comprehensive list of all the medications that are not expected to have clinically relevant interactions with ritonavir-boosted nirmatrelvir. Box 1 includes commonly prescribed medications that are not expected to have clinically relevant interactions with ritonavir-boosted nirmatrelvir. Because ritonavir-boosted nirmatrelvir is the only highly effective oral antiviral for the treatment of COVID-19, drug interactions that can be safely managed should not preclude the use of this medication.Ĭlinicians should be aware that many commonly used medications can be safely coadministered with ritonavir-boosted nirmatrelvir despite its drug-drug interaction potential. Ritonavir may also increase blood concentrations of certain concomitant medications.īefore prescribing ritonavir-boosted nirmatrelvir (Paxlovid) to treat patients with mild to moderate COVID-19, carefully review the patient’s concomitant medications, including over-the-counter medicines, herbal supplements, and recreational drugs.
Ritonavir, a strong cytochrome P450 (CYP) 3A4 inhibitor and a P-glycoprotein inhibitor, is coadministered with nirmatrelvir to increase the blood concentration of nirmatrelvir, thereby making it effective against SARS-CoV-2.
0 kommentar(er)
